Axogen Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while JPMorgan Ultra Short Income ETF trades at $50.48. The key difference: Axogen Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| AXGN | JPST | |
|---|---|---|
Market Cap | $2.06B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $46.19 | $50.78 |
52-Week Low | $11.28 | $50.40 |
Enterprise Value | $1.98B | — |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
JPST trades at $50.44, down 0.02% with a bearish technical signal from moving averages. The ETF focuses on high-quality, short-term bonds, offering monthly dividends and capital preservation. Recent news highlights strong institutional inflows and its role as a cash alternative in volatile markets. Technical indicators show neutral oscillators but overall bearish momentum, with support and resistance clustered around $50.
Outlook remains stable for income-focused investors seeking low duration risk, though rising Treasury yields pose a headwind. Key risks include interest rate sensitivity and credit spread changes. Institutional ownership trends indicate growing advisor interest, supporting its defensive profile in uncertain rate environments.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →